« Back
Home /
GNB2L1 Antibody

GNB2L1 Antibody

Item no.	OABB01687
Manufacturer	AVIVA Systems Biology
Amount	100 ug/vial
Category	Oncology Neuroscience Molecular Targets for Neuroscience Antibodies By Cell Type Carcinoma Immunohistochemistry Western Blot ELISA Primary Antibodies Immunostaining
Type	Antibody Polyclonal
Format	Liquid
Applications	WB, IHC, ELISA
Specific against	Human (Homo sapiens)
Host	Rabbit
Isotype	IgG
Conjugate/Tag	Unconjugated
ECLASS 10.1	32160702
ECLASS 11.0	32160702
UNSPSC	12352203
Alias	CD55 antigen;CD55 molecule,decay accelerating factor for complement (Cromer blood group);CHAPLE;complement decay-accelerating factor;CR;CROM;Cromer blood group antigen;DAF;Rh blood group D antigen;TC.
Available
Manufacturer - Type	Polyclonal Antibody
Manufacturer - Category	Root Catalog/Products/Polyclonal Antibodies, Root Catalog/Products/Primary Antibodies
Gene symbol	CD55
Gene Fullname	CD55 molecule (Cromer blood group)
Product format	Liquid
Reconstitution and storage	-20°C or -80°C
Description of target	Guanine nucleotide-binding protein subunit beta-2-like 1, also known as RACK1 is a 32kDa protein that in humans is encoded by the GNB2L1 gene. It is mapped to 5q35.3. GNB2L1 is a major component of translating ribosomes, which harbor significant amounts of PKC. This gene can provide a physical and functional link between PKC signaling and ribosome activation. GNB2L1 is also a mediator of agonist-induced Ca(2+) release. Whata€s more, GNB2L1 is an essential component of an oxygen-independent mechanism for regulating HIF1A stability. Overexpression of GNB2L1 and PKC-alpha suppressed CLOCK-BMAL1 transcriptional activity, and GNB2L1 stimulated phosphorylation of BMAL1 by PKC-alpha in vitro.
Protein name	Complement decay-accelerating factor
Clonality	Recombinant Monoclonal
Purification	Affinity Purified
Immunogen	A synthesized peptide derived from human CD55
Dilution	This protein recognizes C4b and C3b fragments that condense with cell-surface hydroxyl or amino groups when nascent C4b and C3b are locally generated during C4 and c3 activation. Interaction of daf with cell-associated C4b and C3b polypeptides interferes with their ability to catalyze the conversion of C2 and factor B to enzymatically active C2a and Bb and thereby prevents the formation of C4b2a and C3bBb, the amplification convertases of the complement cascade (PubMed:7525274). Inhibits complement activation by destabilizing and preventing the formation of C3 and C5 convertases, which prevents complement damage (PubMed:28657829).

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

OABB01687-datasheet.pdf

Request safety datasheet

Simple Order Order Subscription

Amount: 100 ug/vial

available

Delivery expected until 12/25/2025

Express Delivery: Save 1 days

Compare

Add to wishlist

Get an offer